Zeneca Zomig (311C) NDA filing for migraine expected later this year.
Executive Summary
ZENECA ZOMIG (311C) FOR MIGRAINE NDA FILING LATER THIS YEAR is anticipated after the company completes analysis of Phase III trial data, Zeneca CEO David Barnes stated at the Bear Stearns health care conference Sept. 11 in New York City. "Phase III trials are complete," he noted. Zomig was acquired from Glaxo Wellcome as a result of a Federal Trade Commission- ordered divestiture: Burroughs Wellcome developed 311C, while Glaxo markets Imitrex ("The Pink Sheet" March 20, 1995, p. 11). FTC cleared the acquisition by Zeneca earlier in September.